

# Buy

## Bank Mandiri (BMRI IJ)

### Nov24 bank-only results: Soft net profit on lower NIM and lower recovery income

Last Price (Rp)	5,675
Target Price (Rp)	8,200
Upside/Downside	+44.5%
No. of Shares (mn)	93,333
Mkt Cap (Rpbn/US\$m)	615,330/32,706
Avg, Daily T/O (Rpbn/US\$m)	653.2/40.3

- **BMRI's Nov24 net profit was soft at Rp4.1tr (+1% mom, -10% yoy), impacted by higher CIR and lower NIM, despite reduced CoF**
- **BMRI's 11M24 net profit rose to Rp47.2tr (+5% yoy), i.e., below, driven by a 23% loan growth, which offset NIM compression due to rising CoF.**
- **BMRI's overall performance was relatively weak, marked by declining NIM, though deposit growth and lower CoF showed some positives.**

#### Key Financials:

	2024F	2025F	2026F
EPS (Rp)	608.8	672.7	706.1
PER (x)	9.3	8.4	8.0
PBV (x)	1.9	1.7	1.6
CoE (x)	12.6	13.6	14.1
Dividend yield (%)	6.4	7.1	7.5
ROAE (%)	20.9	21.2	20.5

#### 11M24 Insights:

- **Net profit rose 5% yoy:** BMRI reported a net profit of Rp47.2tr (+5% yoy), achieving 83% of both our and consensus FY24F, slightly trailing last year's performance of 86%.
- **Strong loan growth offset the lower NIM:** Loans increased 23% yoy, while deposits rose 15% yoy, resulting in a higher LDR of 93.9% in 11M24 compared to 87.7% in 11M23. This drove positive NII growth (+5%) despite a 44bps yoy decline in NIM to 4.9%.
- **NIM pressured by higher CoF:** EA yield remained stable at 7.3%, but CoF increased to 2.8% (from 2.2% in 11M23), contributing to the lower NIM amidst a higher LDR.
- **Stable CoC:** As of 11M24, BMRI's CoC was steady at 0.7% (flat yoy), with provision expenses increasing 23%, aligned with the 23% loan growth.
- **Opex efficiency and improved CIR:** BMRI's opex rose only 1% yoy in 11M24, leading to an improved CIR of 33.2%, down from 34.4% in 11M23.

#### Nov24 Insights:

- **Soft Nov24 net profit:** BMRI reported net profits of Rp4.1tr (+1% mom, -10% yoy), impacted by lower other operating income, higher opex, and a reduced NIM.
- **NIM fell mom despite a decline in CoF:** CoF decreased by 19bps mom, but a 31bps drop in EA yield led to a lower NIM of 4.7% (-17bps mom).
- **Lower LDR mom as deposits grew faster than loans:** Loans grew 2% mom, while deposits rose 3%, reducing LDR to 93.9% in Nov24 from its Oct24 high of 95.1%.
- **CoC normalized at 0.3%:** Following a high base in Oct24, CoC moderated to 0.4% in Nov24 (-61bps mom).
- **Higher CIR due to lower income:** With a declining NIM and a drop in other operating income (-4% mom, -19% yoy), CIR increased to 38.6% in Nov24.

#### Summary:

- **Overall performance:** In our assessment, BMRI's Nov24 results were relatively weak, with a declining NIM and recovery income failing to match last year's levels. LDR remained high, but the lower CoF and a 3% mom deposit growth showed positive momentum.
- We currently have a **Buy** rating on BMRI with TP of Rp8,200 (based on a 5-year inverse cost of equity GGM).

#### BRI Danareksa Sekuritas Analysts

##### Victor Stefano

(62-21) 5091 4100 ext. 3503

victor.stefano@brids.co.id

##### Naura Reyhan Muchlis

(62-21) 5091 4100 ext. 3507

naura.muchlis@brids.co.id

**Exhibit 1. BMRI Nov24 bank-only results**

BMRI - Bank Only (Rpbn)	Nov-23	Oct-24	Nov-24	mom, %	yoy, %	11M23	11M24	yoy, %	FY23	11M23/FY23	FY24F	11M24/FY24F	FY24C	11M24/FY24C
Interest income	8,298	9,927	9,607	-3%	16%	88,946	101,698	14%	97,831	91%	149,120	68%		
Interest expense	(2,456)	(3,434)	(3,279)	-5%	33%	(23,803)	(33,147)	39%	(26,604)	89%	(47,692)	70%		
<b>Net interest income</b>	<b>5,842</b>	<b>6,493</b>	<b>6,328</b>	<b>-3%</b>	<b>8%</b>	<b>65,144</b>	<b>68,551</b>	<b>5%</b>	<b>71,227</b>	<b>91%</b>	<b>101,429</b>	<b>68%</b>	<b>103,952</b>	<b>66%</b>
Other operating income	3,113	2,646	2,527	-4%	-19%	28,091	28,646	2%	32,452	87%	44,138	65%	45,237	63%
Operating expenses	(3,378)	(3,414)	(3,422)	0%	1%	(32,051)	(32,278)	1%	(35,623)	90%	(56,737)	57%		
<b>PPOP</b>	<b>5,578</b>	<b>5,725</b>	<b>5,433</b>	<b>-5%</b>	<b>-3%</b>	<b>61,184</b>	<b>64,918</b>	<b>6%</b>	<b>68,056</b>	<b>90%</b>	<b>92,878</b>	<b>70%</b>		
Provision	(24)	(954)	(328)	-66%	1250%	(5,844)	(7,167)	23%	(5,367)	109%	(15,368)	47%	(14,032)	51%
Pre-tax profit	5,588	5,034	5,103	1%	-9%	55,416	58,095	5%	62,787	88%	77,553	75%	77,354	75%
<b>Net profit</b>	<b>4,554</b>	<b>4,055</b>	<b>4,111</b>	<b>1%</b>	<b>-10%</b>	<b>45,069</b>	<b>47,173</b>	<b>5%</b>	<b>51,097</b>	<b>88%</b>	<b>56,817</b>	<b>83%</b>	<b>56,634</b>	<b>83%</b>
										YTD, %				
Loans	1,046,059	1,263,845	1,283,445	2%	23%	1,046,059	1,283,445	23%	1,085,787	18%	1,599,449	80%	1,622,421	79%
Customer deposits	1,192,237	1,328,960	1,367,083	3%	15%	1,192,237	1,367,083	15%	1,242,146	10%	1,804,456	76%	1,758,145	78%
<b>Key Ratio</b>				mom, bps	yoy, bps			yoy, bps		11M24 vs FY23, bps		vs FY24F, bps		
Earning Asset yield (%) - ann	7.2	7.4	7.1	↓ (31)	↓ (10)	7.3	7.3	⇒ (2)	7.3	⇒ (3)	7.2	↑ 13		
Cost of fund (%) - ann	2.5	3.1	2.9	↑ (19)	↓ 43	2.2	2.8	↓ 55	2.3	↓ 51	2.5	↓ 27		
NIM (%) - ann	5.1	4.9	4.7	↓ (17)	↓ (39)	5.3	4.9	↓ (44)	5.3	↓ (41)	4.9	⇒ 4		
CIR (%) - ann	37.7	37.4	38.6	↓ 129	↓ 93	34.4	33.2	↑ (117)	34.4	↑ (115)	37.9	↑ (471)		
Cost of credit (%) - ann	0.0	0.9	0.3	↑ (61)	↓ 28	0.7	0.7	⇒ 1	0.5	↓ 12	1.0	↑ (37)		
CASA Ratio (%)	79.1	78.4	79.5	↑ 112	↑ 40	79.1	79.5	↑ 40	79.4	⇒ 8	63.5	↑ 1,602		
LDR (%)	87.7	95.1	93.9	↑ (122)	↓ 614	87.7	93.9	↓ 614	87.4	↓ 647	88.6	↓ 524		

Source: Company, BRIDS Estimates, Bloomberg

**BRI Danareksa Equity Research Team**

Erindra Krisnawan, CFA	Head of Equity Research, Strategy, Coal	<a href="mailto:erindra.krisnawan@brids.co.id">erindra.krisnawan@brids.co.id</a>
Natalia Sutanto	Consumer, Cigarettes, Pharmaceuticals, Retail	<a href="mailto:natalia.sutanto@brids.co.id">natalia.sutanto@brids.co.id</a>
Niko Margaronis	Telco, Tower, Technology, Media	<a href="mailto:niko.margaronis@brids.co.id">niko.margaronis@brids.co.id</a>
Timothy Wijaya	Metal, Oil and Gas	<a href="mailto:timothy.wijaya@brids.co.id">timothy.wijaya@brids.co.id</a>
Victor Stefano	Banks, Poultry	<a href="mailto:victor.stefano@brids.co.id">victor.stefano@brids.co.id</a>
Ismail Fakhri Suweleh	Healthcare, Property, Industrial Estate	<a href="mailto:ismail.suweleh@brids.co.id">ismail.suweleh@brids.co.id</a>
Richard Jerry, CFA	Automotive, Cement, Infrastructure	<a href="mailto:richard.jerry@brids.co.id">richard.jerry@brids.co.id</a>
Ni Putu Wilastita Muthia Sofi	Research Associate	<a href="mailto:wilastita.sofi@brids.co.id">wilastita.sofi@brids.co.id</a>
Naura Reyhan Muchlis	Research Associate	<a href="mailto:naura.muchlis@brids.co.id">naura.muchlis@brids.co.id</a>
Sabela Nur Amalina	Research Associate	<a href="mailto:sabela.amalina@brids.co.id">sabela.amalina@brids.co.id</a>
Kafi Ananta Azhari	Research Associate	<a href="mailto:kafi.azhari@brids.co.id">kafi.azhari@brids.co.id</a>

**BRI Danareksa Economic Research Team**

Helmy Kristanto	Chief Economist, Macro Strategy	<a href="mailto:helmy.kristanto@brids.co.id">helmy.kristanto@brids.co.id</a>
Dr. Telisa Aulia Falianty	Senior Advisor	<a href="mailto:telisa.falianty@brids.co.id">telisa.falianty@brids.co.id</a>
Kefas Sidauruk	Economist	<a href="mailto:kefas.sidauruk@brids.co.id">kefas.sidauruk@brids.co.id</a>

**BRI Danareksa Institutional Equity Sales Team**

Yofi Lasini	Head of Institutional Sales and Dealing	<a href="mailto:yofi.lasini@brids.co.id">yofi.lasini@brids.co.id</a>
Novrita Endah Putrianti	Institutional Sales Unit Head	<a href="mailto:novrita.putrianti@brids.co.id">novrita.putrianti@brids.co.id</a>
Ehrlich Suhartono	Institutional Sales Associate	<a href="mailto:ehrliech@brids.co.id">ehrliech@brids.co.id</a>
Yunita Nababan	Institutional Sales Associate	<a href="mailto:yunita@brids.co.id">yunita@brids.co.id</a>
Adeline Solaiman	Institutional Sales Associate	<a href="mailto:adeline.solaiman@brids.co.id">adeline.solaiman@brids.co.id</a>
Andreas Kenny	Institutional Sales Associate	<a href="mailto:andreas.kenny@brids.co.id">andreas.kenny@brids.co.id</a>
Christy Halim	Institutional Sales Associate	<a href="mailto:christy.halim@brids.co.id">christy.halim@brids.co.id</a>
Jason Joseph	Institutional Sales Associate	<a href="mailto:jason.joseph@brids.co.id">jason.joseph@brids.co.id</a>

**BRI Danareksa Sales Traders**

Mitcha Sondakh	Head of Sales Trader	<a href="mailto:mitcha.sondakh@brids.co.id">mitcha.sondakh@brids.co.id</a>
Suryanti Salim	Sales Trader	<a href="mailto:suryanti.salim@brids.co.id">suryanti.salim@brids.co.id</a>

**INVESTMENT RATING**

<b>BUY</b>	Expected total return of 10% or more within a 12-month period
<b>HOLD</b>	Expected total return between -10% and 10% within a 12-month period
<b>SELL</b>	Expected total return of -10% or worse within a 12-month period

**Disclaimer**

The information contained in this report has been taken from sources which we deem reliable. However, none of PT BRI Danareksa Sekuritas and/or its affiliated and/or their respective employees and/or agents makes any representation or warrant (express or implied) or accepts any responsibility or liability as to, or in relation to, the accuracy or completeness of the information and opinions contained in this report or as to any information contained in this report or any other such information or opinions remaining unchanged after the issue thereof.

We expressly disclaim any responsibility or liability (express or implied) of PT BRI Danareksa Sekuritas, its affiliated companies and their respective employees and agents whatsoever and howsoever arising (including, without limitations for any claims, proceedings, action, suits, losses, expenses, damages or costs) which may be brought against or suffered by any person as results of acting in reliance upon the whole or any part of the contents of this report and neither PT BRI Danareksa Sekuritas, its affiliated companies or their respective employees or agents accepts liability for any errors, omissions or mis-statements, negligent or otherwise, in the report and any liability in respect of the report or any inaccuracy therein or omission therefrom which might otherwise arise is hereby expressly disclaimed.

The information contained in the report is not to be taken as any recommendation made by PT BRI Danareksa Sekuritas or any other person to enter into any agreement with regard to any investment mentioned in this document. This report is prepared for general circulation. It does not have regards to the specific person who may receive this report. In considering any investments you should make your own independent assessment and seek your own professional financial and legal advice.